Recall Classification and Communication in Nigeria under NAFDAC Guideline PMS-GDL-020-00

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The recall operating framework in Nigeria is PMS-GDL-020-00, the NAFDAC Guidelines on Recall of Defective Medical Products, effective 30 September 2024. It answers three questions: how to grade, how to communicate, how to track.

  • Grading: recall levels are classified by the degree of health hazard;
  • Communication: for each level (Class I–IV) the guideline prescribes different communication methods and intensities, including recall letters and press releases;
  • Tracking: the recall is subject to progress monitoring until closure.

Its correspondence with the Regulations layer is: Article 12 is the daily obligation, Article 8(1)(c)(d) is the suspension ground, and PMS-GDL-020-00 is the remedy instrument. A recall executed under the guideline does not erase the underlying regulatory risk, but it demonstrates a functioning system and materially improves the company’s position when NAFDAC assesses the event.

2. Legal basis

RegulationReference numberPublication dateProvisions
NAFDAC Recall of Defective Medical ProductsPMS-GDL-020-00Effective 30 September 2024§4 (recall grading), §5 (communication methods, Class I–IV), §6 (progress monitoring)
NAFDAC Medical Devices and Related Products (Registration, Labelling and Advertisement) Regulations, 2024S.I. No. 42 of 202416 October 2024Article 12(2) (the react element of the PMS system), Article 8(1)(c)(d) (suspension grounds), Article 15 (sealing of premises)
NAFDAC Medical Devices GMP Guidelines 2024DER-GDL-025-00Effective 11 November 2024§13.2 (recalls and mock recalls), §11.3–§11.7 (nonconforming product and CAPA)
NAFDAC Post-Market Surveillance GuidelinesPMS-GDL-016-01Effective 27 September 2024Entire text (PMS system)

3. Expert insights

Insight one: recall is the statutory landing point of the react element in Article 12(2).

Article 12(2) requires the PMS system to be able, at a minimum, to monitor, collect, evaluate and react. The first three actions are about finding problems; the reaction must take a concrete form — and recall is the heaviest one. A recall contingency plan is therefore not optional; it is a component of the PMS system. When NAFDAC reviews a company’s PMS arrangements, the existence, rehearsal and traceability of the recall plan are among the first things examined.

Insight two: grading determines communication intensity — the most operationally valuable part of the guideline.

PMS-GDL-020-00 prescribes different communication methods for Classes I–IV. The higher the level, the wider the communication scope and the more formal the method — from a targeted recall letter to a public press release. The practical implication: a company cannot decide on its own to conduct a quiet recall. Once the level is determined, the communication method is prescribed by the guideline, not chosen by the company. Underestimating the level to avoid publicity is itself a compliance failure, and the discrepancy between the hazard and the announced grade is easy for the agency to detect.

Insight three: the GMP guideline requires mock recalls — a hard requirement that is often ignored.

DER-GDL-025-00 §13.2 requires, in addition to recalls, mock recalls. The value of a mock recall lies in validating traceability: whether all destinations of a specific batch can be located within the required time. Without periodic drills, a real recall usually reveals incomplete distribution records and progress monitoring cannot be completed. Set the mock recall as a fixed annual item. The drill report, including the time taken to reach full batch reconciliation, becomes tangible evidence of system readiness.

Insight four: recall and CAPA are two segments of one chain.

DER-GDL-025-00 §11.3–§11.7 govern nonconforming product control, rework and CAPA. Recall is the external disposition; CAPA is the internal correction. Placing the two in adjacent chapters shows NAFDAC’s review logic: after a recall closes, the CAPA is examined, and if the CAPA is ineffective the risk of recurrence remains. A recall report must carry a CAPA plan, with effectiveness-verification checkpoints dated and assigned, not merely described.

Insight five: recall information flows back into registration status and premises risk.

Article 8(1)(c) (non-compliance with quality, performance or safety provisions) and Article 8(1)(e) (premises non-compliance with GMP / GDP / GWP) can both be triggered by a single recall; the sealing of premises under Article 15 is the enforcement instrument. The price of mishandling a recall is the registration certificate itself. Boards should treat recall readiness as a licence-protection expense, not a logistics cost, and fund it accordingly.

4. Practical recommendations

  1. Prepare a recall contingency plan and rehearse it against the grading logic of PMS-GDL-020-00, with named communication owners for each class.
  2. Make the mock recall a fixed annual item (GMP §13.2), focused on validating batch traceability.
  3. Attach a CAPA plan to every recall report (§11.7) with effectiveness-verification milestones.
  4. Retain distribution records completely so that progress monitoring can compute the recall completion rate.
  5. Prepare recall letter and press release templates in advance, selected by class, to avoid wording drift under time pressure.
  6. After a recall, assess whether any Article 8(1) ground is triggered and communicate proactively with NAFDAC where necessary.

5. Verification checklist

  • □ The recall contingency plan has been prepared in line with PMS-GDL-020-00 (effective 30 September 2024).
  • □ The possible recall classes for the company’s products and their corresponding communication methods (Class I–IV) have been identified.
  • □ Mock recalls are in the annual plan and the most recent drill has been completed (GMP §13.2).
  • □ Batch traceability has been validated; all destinations can be located.
  • □ The recall report template includes a CAPA plan section (§11.7).
  • □ Recall letter and press release templates are ready and can be issued within 24 hours.
  • □ After each recall, whether any Article 8(1) suspension ground is triggered has been assessed.

Regulatory information verified as of 29 October 2026. All citations have been checked against the official NAFDAC guidelines (PMS-GDL-020-00, effective 30 September 2024; PMS-GDL-016-01, effective 27 September 2024), the GMP Guidelines (DER-GDL-025-00 §11.3–§11.7, §13.2) and the Regulations text (S.I. No. 42 of 2024, Articles 8(1)(c)(d)(e), 12(2), 15); the specific definitions and criteria of recall classes follow the text of PMS-GDL-020-00.

  • Local resources in Nigeria: GRZAN can coordinate locally licensed importer and authorised representative resources, covering NAPAMS electronic submission, dossier screening permit coordination, import permits, sample delivery and laboratory analysis support.
  • Service capabilities: classification determination, registration pathway selection, technical documentation (IMDRF ToC), CMFS and legalisation, GMP and foreign inspection readiness, advertisement permits, vigilance and PMS reporting, change management and renewal.
  • Contact: hito.lin@grzan.cn; website www.grzan.cn; email info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail